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An electronic medical recordsbased approach to identify
idiosyncratic drug-induced liver
injury in children
Tracy L. Sandritter1, Jennifer L. Goldman1,2, Clayton J. Habiger3, James F. Daniel4,
Jennifer Lowry1 & Ryan T. Fischer 4*
Drug-induced liver injury (DILI) is the leading cause of liver failure in the United States and the most
common cause of drug recall. As opposed to the recognized direct toxicity of super-therapeutic
acetaminophen or chemotherapeutic agents in children, limited data exists for pediatric populations
on the incidence of idiosyncratic DILI (iDILI) that may develop independently of drug dose or duration
of administration. To improve the detection of adverse drug reactions at our hospital, we utilized
electronic medical records-based automated trigger tools to alert providers of potential iDILI. Clinical
criteria concerning for iDILI were defined as serum ALT > 5x or serum bilirubin > 1.5x upper limit of
normal in the setting of medication exposure. Over a two year period, 12 patients were identified as
having possible or probable iDILI. Out of the identified patients, three were males, and the mean age
was 10.8 years. Implicated agents included eight antibiotics, two anti-epileptics, one anti-psychotic,
and one anti-inflammatory medication. Roussel-Uclaf Causality Assessment Methods identified one
“possible” case, 11 “probable” cases, and one “highly probable” case of iDILI. Improved awareness and
more vigilant programming can generate better data on iDILI and improve our understanding of the
condition and its incidence in children.
Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the United States1 and the most
common cause of drug recall from the market2. Recent data demonstrate that in adult patients with confirmed
DILI, one in 10 will need to undergo transplantation and one in six will have evidence of long term liver injury
six months after initial suspected damage3. In an analysis by Mindikoglu and colleagues of 73,977 patients (adults
and children) that underwent transplant from October of 1987 to December of 2006, they identified 661 cases of
drug-induced acute liver failure. Ninety-four of these were in children, with acetaminophen being responsible for
the largest portion of cases (29%)4. The Pediatric Acute Liver Failure Study Group showed that DILI accounted
for 16% of acute liver failure cases in the United States5. Again, the most common etiology was acetaminophen
overdose (12% of all acute liver failure), and 4% were due to non-acetaminophen drug injury5.
While the direct hepatotoxicity of super-therapeutic acetaminophen is well-described6, the less frequent, idiosyncratic causes of DILI (iDILI) in pediatric patients remain poorly understood. Exposure to antimicrobials,
antiepileptics, antidepressants, and medications for attention deficit disorders represent most iDILI cases in children4,7,8. Active surveillance of pediatric iDILI is rare. The diagnosis and—as importantly—the determination of
iDILI causality remains a significant obstacle in clinical practice. This difficulty can be attributed to several key
factors. Clinically, biochemically, and histologically, iDILI can resemble many forms of both acute and chronic
liver injury. Definitive laboratory studies are lacking, further complicating the diagnosis, and determination of
drug causality is limited to scoring systems that were not designed for pediatric patients.
Children’s Mercy Hospital (CMH) is a 354-bed, tertiary care, free-standing children’s hospital in Kansas City,
MO. To better characterize and detect possible adverse drug reactions (ADR) in children, our hospital developed
a campus-wide pharmacovigilance service, the Drug Safety Service (DSS) in October 2010. The DSS is operated
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Figure 1. Workflow for the identification of possible idiosyncratic drug-induced liver injury.

by a dedicated clinical pharmacist in the Division of Clinical Pharmacology, Toxicology, and Therapeutic
Innovation with the support of the Pharmacy Department. A detailed description of the development and operation of the program has been previously described9. The goal of the program is to identify and improve documentation of potential adverse drug reaction cases, and in turn, better understand medications associated with
toxicity and possible preventive strategies. To further enhance the identification of ADR, specifically related to
DILI, EMR triggers were developed and implemented in 2012 to screen patients for potential DILI. Herein, we
assess two years of cases associated with pediatric iDILI and report on the implicated agents as well as associated
clinical and laboratory characteristics in our population.

Results

A total of 3,275 inpatient and outpatient lab values were assessed during the study period with 791 and 2,484 values triggering alanine aminotransferase (ALT) and bilirubin criteria, respectively (Fig. 1). Following the exclusion
of redundant patients (triggers of the same type in the same patient that corresponded to an already assessed case)
a total of 1,515 unique events remained with 453 ALT and 1,062 bilirubin triggers. Both values were triggered
simultaneously in 90 patients. This represents a mean of 3.0 unique triggers to review per week day averaging
five minutes per review. Of the unique ALT triggers, 2.6% (n = 12) were considered possible or probable iDILI
(Table 1). However, 26% of these ALT triggers were associated with chemotherapy. When chemotherapy ALT
triggers were excluded, possible or probable iDILI rose to 3.4%. Of the non-chemotherapy bilirubin triggers, only
0.5% (n = 5) were associated with iDILI. No cases of iDILI were associated with an isolated bilirubin trigger as all
patients had an elevated ALT.
Overall, 67,817 ALT values and 75,306 bilirubin levels were obtained across the inpatient and outpatient settings in our hospital system during the examined years. Focusing on ALT values, these were obtained from 27,130
unique patients in the two years studied. Thus, only 1.6% of the unique patients with ALT levels drawn had a triggering ALT (n = 453), and only 0.04% (n = 12) had iDILI. Interestingly, the inpatient setting accounted for only
8% (n = 2,182) of unique patient ALT levels, but 55% (n = 253) of the observed ALT triggers.

iDILI clinical characteristics. Twelve possible or probable cases of iDILI were found in our assessment and
their characteristics are listed in Table 2. Majority of patients were female (N = 9; 75%) and in early adolescence
with an average age of 10.8 years. Symptoms at the time of presentation varied significantly; fever (n = 7), fatigue
(n = 6), rash, abdominal pain, jaundice (n = 5 for each), arthralgia, nausea/vomiting, and pruritus (n = 4 for each)
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Probable Etiologies of ALT Triggers
Number

Percent of
Total
100.0

All Events

453

Chemotherapy

118

26.0

Infection

68

15.0

Trauma

29

6.4

Congenital Liver Disease

23

5.1

Cardiac Disease

22

4.8

Musculoskeletal Disease

15

3.3

Sepsis

15

3.3

Cholelithiasis/Cholecystitis

14

3.1
2.6

DILI

12

Parenteral Nutrition Use

12

2.6

Unknown

40

8.8

Miscellaneous*

85

18.7

Table 1. Percent of ALT elevations associated with underlying causes. *Includes diagnoses with fewer than 10
cases (e.g., cystic fibrosis, liver transplant, etc.).
iDILI Patient Characteristics
Hospitalized (n = 6)

Outpatient
(n = 6)

Female gender

5 (83%)

4 (67%)

Mean age (years)

10.2

11.4

Hepatitis

5

4

Cholestatic

0

0

Mixed

1

2

p-value
0.74

Injury type (based on R ratio*)

Mean peak ALT (U/L)

1251.7

898.5

0.6

Mean peak bilirubin (gm/dL)

4.6

2.1

0.23

Mean eosinophils (cells/mcL)

0.36

0.12

0.27

3

5

Etiology
Antimicrobials
Oxacillin

1

Minocycline

2

Doxycycline
Azithromycin

1
1

Trimethroprim
Trimethoprim- sulfamethoxazole

1
1

Amoxicillin
Antiepileptics

1
2

Lamotrigine

1

Carbamazepine

1
1

Antipsychotics
Aripiprazole
Anti-inflammatory
Sulfasalazine

1
1
1

Steroid treatment

4 (67%)

0 (0%)

Mean RUCAM

7.5

7.8

0.65

Table 2. Demographic and clinical features of iDILI patients. *R = (ALT value/ALT ULN)/(ALKP value/ALKP
ULN). R > 5 = hepatocellular, R < 2 = cholestatic, R between 2 and 5 = mixed.

were experienced by patients (Table 3). The majority of patients displayed a hepatocellular injury pattern based
on the application of the Roussel-Uclaf Causality Assessment Method (RUCAM)10,11. The RUCAM assessment
first defines whether an injury is “hepatocellular,” “mixed,” or “cholestatic” based on the “R ratio.” Nine patients
had hepatocellular injury with a minority presenting with a mixed pattern (n = 3). No patients presented with a
cholestatic injury pattern alone, as defined by the R ratio (Table 2). Six patients were evaluated for iDILI in the
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Symptoms associated with iDILI
Patient
No.

Jaundice

Joint
pain

1

Fever

Naseua/
vomiting

Abdominal
pain

Fatigue

X

2
3

Rash

X
X

4

X

X

X

X

5

X

6

X

X
X

7

X

X

X

X

X

X
X

X

X

8

X

9

X

X

X

X

X

X
X

Pruritus
X

X

X

X

10
11

X

12

X

X

X

X

X

X

X

Table 3. Reported signs and symptoms in children with iDILI.
inpatient setting, with five of those patient admissions being related to iDILI. Four hospitalized patients had
iDILI with hypersensitivity features, including two with drug reaction with eosinophilia and systemic symptoms
(DRESS) and one that developed hemophagocytic lymphohistiocytosis (HLH). The four patients with hypersensitivity reactions required steroids and hospitalization, while the HLH patient was the only one to develop an
associated coagulopathy. No patient developed liver failure in our series, nor did any patient undergo liver biopsy.

Laboratory values. Of the 12 cases of iDILI described, all 12 triggered our DSS based on ALT and five
triggered based on both ALT and bilirubin levels. No cases were identified using the bilirubin trigger alone. The
mean initial ALT value was 840 U/L, with the mean peak being 1075 U/L for all iDILI cases. The mean initial total
bilirubin level in iDILI patients was 2.7 mg/dL with an average peak value of 3.4 mg/dL. In the majority of cases,
initial ALT and bilirubin values were the peak values, and they did not vary significantly between hospitalized
and non-hospitalized patients. The mean peak ALT in iDILI-related hospitalized patients was 1251.7 U/L and
the mean peak ALT in non-hospitalized patients was 898.5 U/L, with a p-value of 0.6. The mean peak bilirubin
in hospitalized versus non-hospitalized patients was 4.6 and 2.1, respectively (p = 0.28). These data are detailed
in Table 4.
Non-DILI ALT triggers.

Further investigation revealed that ALT elevations attributed to infection (n = 68),
trauma (n = 29), congenital cholestasis (biliary atresia, Alagille, etc.; n = 23), and congenital heart disease (n = 22)
made up the largest proportions of patients with ALT triggers not associated with iDILI (Table 1). Investigation
into the bilirubin triggers revealed that most of the non-iDILI cases were related to physiologic/human milk
jaundice and hemoglobinopathies (e.g., sickle cell disease and thalassemias).

Suspected drugs and causality assessment. Antimicrobials (n = 8) were the most prevalent drug class

associated with DILI. Additionally, anti-epileptics (n = 2), anti-psychotics (n = 1) and anti-inflammatory agents
(n = 1) were identified. Minocycline (n = 2) and trimethoprim-sulfamethoxazole (n = 2) were the most commonly implicated single agents (Table 4). Acne and other bacterial infections were the most common indications
for suspected medication use. The average RUCAM score for all groups was 7.7.

Temporal relationship. Following the first reported dose of a suspected medication, the median time to
initial presentation of symptoms (or lab trigger if asymptomatic) was 28.5 days (range 3 to 731). The EMR trigger
occurred a median of three days (range 0–33) following onset of reported symptoms. The majority of patients had
a relatively benign clinical course, with no chronic liver disease identified in a median of 4.1 years of follow-up
(range 1.8–5.0 years). Six patients were identified and managed in the outpatient setting and did not require
hospitalization. The median number of hospital days for the six hospitalized patients was 13 (range 3–41). The
median time to normalization of ALT following the recognized iDILI was 35 days, with there being no significant
difference between patients managed in the inpatient setting and those seen as outpatients. Hospitalized patients
normalized their ALT in an average of 19.2 days, while the ALT was noted to be in the normal range for outpatient
iDILI patients after an average of 154.3 days (p = 0.15). Outpatients typically did not have the same frequency of
lab draws as inpatients, and they did not receive steroids during recovery.

Discussion

In this study, we have examined the utility of a dedicated pharmacovigilance program in detecting iDILI. In two
years, 12 cases of possible, probable, or highly probable cases of liver injury were identified at our single center,
a rate of detection that compares favorably to the 66 possible or probable pediatric cases identified in a 13-year,
six-center study7,8. This is important in a number of respects. First, our study shows that iDILI detection rates may
increase with implementation of an inpatient and outpatient service dedicated to identification of potential iDILI
cases, and that pediatric iDILI is likely under-recognized. Two, this study emphasizes the fact that medications
prescribed for both serious and relatively benign indications can lead to significant liver injury.
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Time to
Time from
Type of symptoms symptoms
Injury* (days)
to trigger Peak ALT

Peak ALP

Eosinophils
(cells x 103/
Peak GGT Peak Bili mcL)

Hospitalization Type of
RUCAM (days)
Reaction

Patient

Suspected Agent

Age at iDILI
(years)
Sex

1

Oxacillin

6.3

M

1

22

3

898

222

ND

0.4

0.01

7

25 (unrelated)

Hepatitis

2

Minocycline

15.3

F

1

84

0

1131

288

105

1

0

8

0

Hepatitis

3

Lamotrigine

15.9

F

3

75

33

470

294

1146

8.5

0.01

8

41

DIHSHLH

4

Minocycline

16.8

F

1

731

15

1763

184

157

0.9

0.24

8

0

Hepatitis

5

Azithromycin

3.9

F

1

3

0

4438

546

140

10.1

0.13

7

3

Hepatitis

6

Doxycyline

16.8

F

3

92

6

344

214

136

3.4

0.03

8

0

Hepatitis

7

Sulfasalazine

3.7

F

1

21

8

463

201

ND

0.9

1.2

8

13

DIHSDRESS

8

Aripiprazole

11.0

M

1

32

0

206

43

31

0.7

0.12

5

0

Hepatitis

9

Carbamazepine

16.9

F

1

8

3

814

69

115

0.4

0.2

7

13

DIHS

10

Trimethoprim

1.2

M

1

213

0

944

292

ND

0.3

0.12

10

0

Hepatitis

11

Trimethoprim14.6
sulfamethoxazole

F

3

25

6

427

313

ND

7.2

0.6

8

8

DIHSDRESS

12

Amoxicillin

F

3

8

0

1003

276

ND

6.6

0.2

8

0

Hepatitis

7.3

Table 4. Detailed clinical features of iDILI patients. *(1 = hepatocellular; 2 = cholestatic; 3 = mixed).
DIHS = drug-induced hypersensitivity; HLH = hemophagocytic lymphohistiocytosis; DRESS = drug reaction
with eosinophilia and systemic symptoms.

Detection and identification of iDILI is challenging for multiple reasons. As with other drug-induced diseases, the diagnosis of DILI is a diagnosis of exclusion or all other possible cause (e.g., Hep A, B, C infection,
alpha-1-antitrypsin, Wilson’s disease). Drug exposure correlation is highly variable (days to months)12. The time
of onset of liver dysfunction varies depending on the drug and the patient and can be long after the first ingestion
of drug which might provide a false security that there is not a drug induced cause. For example minocycline and
atomoxetine are both noted to have a prolonged latency (minocycline: median 569 days (range 196–647) and
atomoxetine: median 510 days (range 117–699))7.
Additionally, unique diagnostic difficulties exist for determining iDILI in pediatrics. Specifically, the current
laboratory assessment for DILI included the use of alkaline phosphate. Alkaline phosphatase is expressed in liver
tissues and increases during cholestasis. However, increased serum alkaline phosphate can be a result of accelerated bone growth and excessive enzyme secretion by osteoblasts in children and therefore is a poor marker of
DILI in children13. The RUCAM, the primary DILI causality assessment tool, requires the measurement of the
alkaline phosphatase (ALKP) to ALT ratio to characterize injury. Substituting measurement of gamma-glutamyl
transferase (GGT) for ALKP should be studied in iDILI causality assessments. We noted that the GGT, when
measured, increased in conjunction with the transaminases and bilirubin. Some cases of cholestasis had higher
GGT elevations than others. We would presume that GGT may more accurately correspond to a cholestatic iDILI
response relative to alkaline phosphatase. Unfortunately, GGT is not part of the standard liver panel at many
centers (including our own) and we have limited data on GGT significance in DILI. The necessary integration of
an unreliable marker (alkaline phosphatase) in pediatric patients may confound the score and merits the development of a novel pediatric causality assessments.
Liver biopsy may be helpful in identifying microscopic changes that differentiate DILI from liver injury of
other origins, though it is not an obligatory part of the DILI workup14. DILI may present histologically in the form
of a number of different liver diseases, and biopsies may be non-specific. As reviewed by Teschke and Frenzel15,
anywhere from 13–65% of patients in DILI case series from the past two decades undergo biopsy. Interestingly,
no patient in our series underwent liver biopsy. A rapid recovery in most patients was observed following withdrawal of the implicated drug, sometimes in combination with immunosuppressive therapy, thus eliminating
the necessity of biopsy. While biopsy may indeed be important in assessing more chronic forms of liver injury
(or in differentiating severe—and potentially treatable—autoimmune disease from other forms of injury) drug
withdrawal and monitoring were sufficient in our group. We recommend approaching the need for biopsy on a
case-by-case basis, as a lack of histologic specificity may not justify procedural risk15.
Of note, chronic liver injury (defined as continued injury six months after initial diagnosis by the DILI
Network16) did not develop in any of our patients to the best of our knowledge. One patient in the group died
from complications of respiratory failure and sepsis in the setting of progressive dysautonomia associated with
a previous traumatic brain injury. Hepatitis and liver dysfunction did not contribute to the death in that case.
Overall, our patients would compare favorably to the 17% rate of chronic DILI reported in adults16, recognizing that older age is a recognized risk factor for the development of chronic DILI17. They would also compare
favorably to Kumar and colleague’s report, where 11% of pediatric patients had a DILI-related death, and 14%
went on to develop chronic disease. However, this report was notable in that three-fourths of cases were caused
by complementary and alternative medicines and anti-tuberculosis agents18. These agents were not identified
in our population. In contrast, in an updated report from the DILI Network that analyzed pediatric patients
in the United States, liver failure was noted in 5% of iDILI patients, and chronic disease developed in 17% of
patients7,8. We must acknowledge that our long-term assessment was based on up to five years of chart follow-up,
and not on a repeat clinic visit, imaging or lab values after normalization of transaminases. Chronic injury can
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be asymptomatic, and specific screening for long-term complications (e.g., steatosis, peliosis hepatitis, nodular
regenerative hyperplasia, etc.17) was not done.
As in other reports on pediatric DILI, antimicrobials were the most prevalent drug class associated with iDILI
in our population7,8. Minocycline, used for the treatment of acne, was implicated twice in our identified cases of
iDILI. All patients had a positive anti-nuclear antibody (ANA) screen, and symptoms suggesting an autoimmune
presentation, including rash, athralgias, and fatigue. DILI attributed to minocycline is well recognized19–21 and
continues to be a common example of drug-induced autoimmune hepatitis7,8,22,23. A Cochrane database study
revealed that minocycline did not have a superior efficacy compared to other tetracyclines, however, and that
the risk of autoimmune-type side effects of increased with duration of use24. Another review found doxycycline
was efficacious as minocycline but with a smaller decreased risk of DILI25. We conclude that regular liver enzyme
monitoring should be implemented with minocycline and—if possible—avoiding the medication altogether for
the treatment of acne may be prudent.
This study is limited by its retrospective design and by the fact it represents cases at a single center. Also, our
criteria for DILI were based on the work of Aithal and colleagues14, and do not necessarily reflect the same criteria
set forth by other centers and consortia7,8,26. The lack of specific biomarkers makes the diagnosis of DILI dependent on the interpretation of laboratory, radiographic and/or histologic investigations to rule-out other causes of
liver disease. Such interpretation might rely on expert consensus. For example, the DILI Network provided the
following criteria for identifying iDILI in patients older than two years: clinical suspicion of hepatotoxicity combined with an aspartate aminotransferase (AST) or ALT of >5 times the ULN for the local center (or >5 times the
pre-drug average) or ALKP > 2 times the ULN or pre-drug average, or serum bilirubin > 2.5 mg/dL along with
any elevations in AST, ALT, or ALKP levels, or an internationalized normal ratio (INR) > 1.5 with any elevations
in AST, ALT, or ALKP levels. And, ultimately, causality was determined by their own expert committee, with the
DILIN Causality Committee using both RUCAM and the DILIN Causality Assessment score to determine the
presence of DILI7,8,26.
Other published methods of identifying iDILI in large electronic record datasets have been explored. Methods
have included searching for iDILI using the International Classification of Diseases-9th edition or -10th edition
(ICD-9 or ICD-10) codes that are widely used to classify patients’ principal diagnoses. However, the codes lack
specificity in the ICD-9 and ICD-10 index for iDILI, and the system relies on the medical knowledge of the
coding staff to correctly enter the diagnosis27,28. Text searching methods may be an additional tool to identify
iDILI, but efforts require specific language in patient notes, and case detection sensitivity may be sacrificed with
increased search term efficiency29. That said, the approach our center used in identifying iDILI may be useful in
future multi-center studies—perhaps in combination with previously examined strategies—to better identify and
collect data on patients.
The majority of pediatric DILI reports have focused on hospitalized cases of DILI7,8,30. Our ADR mechanisms
were able to detect potential iDILI in affiliated outpatient settings in addition to hospitalized patients. Thus, less
severe, but perhaps no less important cases of iDILI were identified. In two years of iDILI identification, half of
all cases (including one patient that sustained liver injury without any symptoms) were managed solely in the
outpatient setting. Drug discontinuation was the only treatment necessary for these patients. Understanding what
factors play roles in preventing hospitalizations related to iDILI, and quickly predicting cases that may progress
to more serious disease is an imperative area of further study.

Conclusion

DILI represents a potentially life-threatening and preventable cause of liver injury. Better mechanisms for understanding and predicting injury are desperately needed to prevent harm to thousands of children annually. We
reviewed our experience with a hospital-wide adverse drug reaction reporting system, and identified a number
of cases of suspected iDILI, at a rate that is higher than previously reported from other multicenter trials. Such
approaches applied across an institution or institutions could better identify and define iDILI and improve our
understanding of this enigmatic condition.

Materials and Methods

Data from subjects was collected and reviewed as part of the CMH Institutional Review Board-approved DSS
ADR-detection project from January 1, 2012 to December 31, 2013. All procedures performed in studies involving human participants were in accordance with the ethical standards of the CMH Institutional Review Board
and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of
retrospective study, written informed consent was waived by the CMH Institutional Review Board.
As part of the ADR-detection project, an automated daily report is generated using SAP BusinessObjects
(Walldorf, Germany) which searches laboratory data in the electronic medical record (EMR; Cerner, Kansas City,
MO) and sorts data based on the specific criteria defined by the user. Selected criteria to detect potential DILI
included serum ALT > 5x ULN and/or total serum bilirubin > 1.5x ULN which were based on clinical chemistry
criteria for DILI as established by Aithal et al.14. For reference, the upper limit of normal identified at CMH for
ALT is 50 U/L for all ages and for total bilirubin is 1.2 mg/dL in children older than 6 months. A dedicated clinical
pharmacist then reviews the medical history of all patients meeting trigger criteria (Fig. 1). Patients were excluded
if a known underlying diagnosis was associated with abnormal liver enzyme elevation. Identification of possible
contributing medications was based on the known side effect profile for the medications the child was receiving
and the drug exposure timeline relative to the triggered laboratory result. When a possible iDILI was recognized,
the clinical pharmacist would contact and discuss the case with the prescribing physician. The prescribing physician determined the course of action or possible referral for further evaluation. If the drug was implicated as
a possible cause of the liver injury, the ADR profile was updated to recognize the iDILI side effect including the
severity assessment.
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The injury relationship was further defined by application of the RUCAM10,11. The RUCAM assessment first
defines whether an injury is “hepatocellular,” “mixed,” or “cholestatic” based on the R ratio. This ratio is calculated
by dividing the ALT by the ALKP using multiples of the local upper limit of normal for both values. As such,
R = (ALT value/ALT ULN)/(ALKP value/ALKP ULN). R ratios of >5 define a hepatocellular injury, <2 a cholestatic injury, and between 2 and 5 a mixed injury. The RUCAM score then categorizes patients into “definite or
highly probable” (score > 8), “probable” (score 6–8), “possible” (score 3–5), “unlikely” (score 1–2) and “excluded”
(score </ = 0) cases of iDILI. All cases deemed possible, probably, or definite where included in the study. Patients
receiving chemotherapy and patients with acetaminophen toxicity were excluded from further evaluation after
identification.
Received: 23 August 2019; Accepted: 30 October 2019;
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